<DOC>
	<DOCNO>NCT00262288</DOCNO>
	<brief_summary>The purpose multi-center study explore efficacy , safety , tolerability pharmacokinetics/pharmacodynamics recombinant human C1 inhibitor treatment acute attack patient hereditary angioedema .</brief_summary>
	<brief_title>Recombinant Human C1 Inhibitor Treatment Acute Attacks Patients With Hereditary Angioedema</brief_title>
	<detailed_description />
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas , Hereditary</mesh_term>
	<mesh_term>Complement C1 Inactivator Proteins</mesh_term>
	<criteria>Main inclusion Criteria : Clinical laboratory diagnosis HAE Plasma level functional C1INH le 50 % normal Severe attack abdominal , facialoropharyngeal , genitourinary and/or peripheral HAE . Main exclusion Criteria : Acquired angioedema Pregnancy breastfeed Participation another clinical study within prior 3 month</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>